Locoregional Treatment of Glioblastoma With Targeted α Therapy

医学 多塔 总体生存率 内科学 胶质母细胞瘤 不利影响 肿瘤科 核医学 癌症研究 体内 生物 生物技术
作者
Leszek Królicki,Jolanta Kunikowska,Frank Bruchertseifer,Radosław Kuliński,Dariusz Pawlak,Henryk Koziara,Rafał Rola,Alfred Morgenstern,Adrian Merlo
出处
期刊:Clinical Nuclear Medicine [Ovid Technologies (Wolters Kluwer)]
卷期号:48 (5): 387-392 被引量:10
标识
DOI:10.1097/rlu.0000000000004608
摘要

Glioblastoma (GB) is the most malignant primary brain tumor. Therefore, introduction of new treatment options is critically important. The aim of this study was to assess local treatment with α emitters [ 213 Bi]Bi-DOTA-substance P (SP) and [ 225 Ac]Ac-DOTA-SP.Treatment was performed as salvage therapy in patients with recurrent primary and secondary GB. [ 213 Bi]Bi-DOTA-SP with injected activity 1.85 GBq per cycle was used in 20 primary (48.2 ± 11.8 years old) and in 9 secondary (38.8 ± 10.8 years old) GB patients and [ 225 Ac]Ac-DOTA-SP in 15 primary (45.1 ± 9.9 years old) and in 6 secondary (37.8 ± 6.4 years old) GB patients with a dose escalation scheme (10, 20, and 30 MBq).Local treatment with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP was well tolerated with only few adverse effects. There was no statistically significant difference between [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP groups in survival parameters. For primary GB, survival parameters of patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows(in months): progression-free survival time, 2.7 versus 2.4; OS-d (overall survival from time of diagnosis to death from any cause), 23.6 versus 21.0; OS-t (overall survival from the start of treatment to death from any cause), 7.5 versus 5.0; and OS-r (overall survival from recurrence in primary tumors to death from any cause), 10.9 versus 12.0. Survival parameters of secondary GB patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows (in months): progression-free survival time, 5.8 versus 2.4; OS-d, 52.3 versus 65.0; OS-t, 16.4 versus 16.0; and OS-c (overall survival from conversion into secondary GB multiforme to death from any cause), 18.4 versus 36.0.The similarity results of 213 Bi or 225 Ac may suggest that the local treatment of brain tumors can be greatly simplified. The experience to date shows that local radioisotope treatment of brain tumors requires further dosimetry studies, taking into account the complexity of biological processes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
乐乐应助狂野世立采纳,获得10
刚刚
yzz完成签到,获得积分10
刚刚
刚刚
SYLH应助曾水采纳,获得10
刚刚
刚刚
科研通AI5应助科研通管家采纳,获得10
1秒前
酷波er应助科研通管家采纳,获得10
1秒前
充电宝应助科研通管家采纳,获得10
1秒前
爆米花应助科研通管家采纳,获得10
1秒前
陈佳琪发布了新的文献求助30
1秒前
思源应助科研通管家采纳,获得10
1秒前
1秒前
pluto应助科研通管家采纳,获得10
1秒前
小二郎应助科研通管家采纳,获得10
1秒前
1秒前
田様应助科研通管家采纳,获得10
1秒前
单复天完成签到,获得积分10
2秒前
2秒前
jgy应助科研通管家采纳,获得30
2秒前
2秒前
大模型应助科研通管家采纳,获得10
2秒前
shouyu29应助科研通管家采纳,获得10
2秒前
NexusExplorer应助科研通管家采纳,获得10
2秒前
科研通AI5应助科研通管家采纳,获得10
2秒前
小蘑菇应助科研通管家采纳,获得10
2秒前
上官若男应助科研通管家采纳,获得10
2秒前
科研通AI5应助科研通管家采纳,获得10
2秒前
小二郎应助科研通管家采纳,获得10
2秒前
科研通AI5应助科研通管家采纳,获得10
2秒前
乐乐应助科研通管家采纳,获得10
3秒前
慕青应助科研通管家采纳,获得10
3秒前
yx发布了新的文献求助10
3秒前
科研通AI5应助科研通管家采纳,获得10
3秒前
bkagyin应助科研通管家采纳,获得10
3秒前
3秒前
3秒前
3秒前
3秒前
3秒前
易安完成签到 ,获得积分10
4秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527723
求助须知:如何正确求助?哪些是违规求助? 3107826
关于积分的说明 9286663
捐赠科研通 2805577
什么是DOI,文献DOI怎么找? 1539998
邀请新用户注册赠送积分活动 716878
科研通“疑难数据库(出版商)”最低求助积分说明 709762